GenMark Diagnostics Inc. (NASDAQ:GNMK)’s share price traded up 2.3% on Friday . The company traded as high as $9.74 and last traded at $9.70, with a volume of 61,022 shares changing hands. The stock had previously closed at $9.48.

A number of equities analysts have weighed in on the stock. Needham & Company LLC reissued a “buy” rating on shares of GenMark Diagnostics in a research report on Wednesday, May 4th. Canaccord Genuity reissued a “buy” rating on shares of GenMark Diagnostics in a research report on Wednesday, June 8th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $8.43.

The firm has a 50 day moving average of $8.86 and a 200-day moving average of $6.51. The firm’s market cap is $415.90 million.

GenMark Diagnostics (NASDAQ:GNMK) last released its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.01. The firm had revenue of $11.06 million for the quarter, compared to analyst estimates of $10.67 million. During the same quarter in the prior year, the company earned ($0.24) EPS. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. Equities research analysts expect that GenMark Diagnostics Inc. will post ($1.23) EPS for the current year.

Other hedge funds and institutional investors have added to or reduced their stakes in the company. Morgan Stanley increased its position in GenMark Diagnostics by 10,433.5% in the fourth quarter. Morgan Stanley now owns 1,338,286 shares of the company’s stock worth $10,385,000 after buying an additional 1,325,581 shares in the last quarter. I.G. Investment Management LTD. increased its position in GenMark Diagnostics by 0.7% in the fourth quarter. I.G. Investment Management LTD. now owns 134,589 shares of the company’s stock worth $1,044,000 after buying an additional 978 shares in the last quarter. Finally, Jennison Associates LLC increased its position in GenMark Diagnostics by 7.3% in the fourth quarter. Jennison Associates LLC now owns 3,144,434 shares of the company’s stock worth $24,401,000 after buying an additional 214,822 shares in the last quarter.

GenMark Diagnostics, Inc (GenMark) is a molecular diagnostics company. The Company focuses on developing and commercializing its eSensor detection technology. Its eSensor electrochemical technology detects multiple distinct biomarkers in a single sample. It sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.